pacman schreef op 5 september 2021 11:59:
[...]
om deze reden..??
Anakinra (kineret)
Inhibits IL-1, which is vital in the immune response to SAR-CoV-2;
Indicated for treatment of rheumatoid arthritis, Still’s disease and cryopyrin-associated periodic syndromes;
Might help to neutralise the cause of acute respiratory distress syndrome (ARDS) among patients with COVID-19;
Anakinra has been used (off label) for cytokine storm syndromes triggered by other viruses and is reported to be relatively well tolerated, with a favourable safety profile.
Evidence
On 19 July 2021, the EMA announced that it had started evaluating an application to extend the use of Kineret (anakinra) to include treatment of coronavirus disease 2019 (COVID-19) in adult patients with pneumonia who are at risk of developing severe respiratory failure;
Anakinra did not improve outcomes in patients with mild-to-moderate COVID-19 pneumonia. Further studies are needed to assess the efficacy of anakinra in other selected groups of patients with more severe COVID-19 (The CORIMUNO-19 collaborative group, 22 January 2021).